Loading...
EIGR.Q logo

Eiger BioPharmaceuticals, Inc.OTCPK:EIGR.Q 株式レポート

時価総額 US$12.6m
株価
n/a
私の公正価値
n/a
1Y-5.6%
7D0%
1D
ポートフォリオ価値
​
表示

Eiger BioPharmaceuticals, Inc.

OTCPK:EIGR.Q 株式レポート

時価総額：US$12.6m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Eiger BioPharmaceuticals（EIGR.Q）株式概要

アイガー・バイオファーマシューティカルズ社は、商業段階のバイオ医薬品会社で、肝炎デルタウイルス（HDV）およびその他の重篤な疾患に対する治療法の開発に注力している。 詳細

EIGR.Q ファンダメンタル分析
スノーフレーク・スコア
評価2/6
将来の成長0/6
過去の実績0/6
財務の健全性0/6
配当金0/6

リスク分析

マイナスの株主資本

過去5年間で収益は年間9.7%減少しました。

意味のある時価総額がありません ( $13M )

US市場と比較した過去 3 か月間の株価の変動


EIGR.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Eiger BioPharmaceuticals, Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要Eiger BioPharmaceuticals
過去の株価
現在の株価US$8.50
52週高値US$16.00
52週安値US$1.10
ベータ2.78
1ヶ月の変化-15.00%
3ヶ月変化-24.11%
1年変化-5.59%
3年間の変化-95.66%
5年間の変化-97.13%
IPOからの変化-98.22%

最新ニュース

Recent updates

分析記事 • Apr 01

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders that were waiting for something to happen have been dealt a...
分析記事 • Jan 04

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders won't be pleased to see that the share price has had a very...
分析記事 • Dec 20

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

The latest analyst coverage could presage a bad day for Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ), with the...
分析記事 • Nov 09

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Shareholders in Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) may be thrilled to learn that the analysts have just...
分析記事 • Oct 06

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Seeking Alpha • Oct 05

Eiger sheds ~20% on abandonment of EUA request for COVID therapy

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a biotech focused on rare and ultra-rare diseases, slipped ~20% pre-market Wednesday after announcing it would not seek an emergency use authorization (EUA) application in the U.S. for COVID-19 therapy peginterferon lambda. The decision followed a pre-EUA meeting the company had requested from the FDA. The agency denied the request citing issues in an investigator-sponsored trial designed to assess different therapeutic agents, including peginterferon, in non-hospitalized patients with mild-to-moderate COVID-19. FDA has determined that “any authorization request based on these data is unlikely to meet the statutory criteria for issuance of an EUA in the current context of the pandemic,” the company said. Instead, the agency has suggested that EIGR consider requesting an end-of-Phase 2 meeting to run a company-sponsored pivotal trial targeted at a Biologics License Application (BLA). EIGR is weighing the next steps, including strategic options to advance peginterferon lambda against respiratory viral agents, including COVID-19. Read: In September, the FDA updated its COVID-19 test policy to cut the number of reviews of EUA requests for diagnostic tests.
Seeking Alpha • Sep 06

Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy

The shares of commercial-stage biotech Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) fell ~21% in the pre-market Tuesday after the company announced that the FDA is uncertain about the regulatory path for COVID-19 therapy peginterferon lambda. The update comes after the company's meeting with the regulator regarding the Phase 3 TOGETHER study for peginterferon lambda aimed at its emergency use authorization (EUA). Following the meeting, the FDA has indicated its uncertainty if the company can meet the requirements for a EUA submission for peginterferon lambda. However, EIGR remains in talks with the FDA as the regulator indicated its intention to consider any new data from the TOGETHER trial to support a EUA while the company plans to further develop the candidate in COVID-19.
Seeking Alpha • Jul 26

Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst

European Commission granted marketing authorization for Zokinvy (lonafarnib) for the treatment of patients with progeria on July 20, 2022. Results from the phase 3 D-LIVR study using Lonafarnib for the treatment of patients with Hepatitis Delta Virus are expected by end of 2022. In March of 2022, a single dose of peginterferon Lambda for Covid-19, reduced the risk of hospitalization or ER visits greater than 6 hours by 50% in a predominantly vaccinated population. An Emergency Use Authorization filing from Eiger BioPharmaceuticals to the FDA for peginterferon Lambda for Covid-19 is possible in 2022. Eiger BioPharmaceuticals (EIGR) is a great speculative biotech play to look into. That's because it has a major catalyst for investors to look forward to at the end of 2022. This would be the readout of the phase 3 D-LIVR study, which is using Lonafarnib for the treatment of patients with Hepatitis Delta Virus ((HDV)). There is potential here to eventually possibly obtain approval for two combinations. These combinations include Lonafarnib and ritonavir and in combination with peginterferon alfa. In addition, this biotech had already received European approval for its treatment Zokinvy (Lonafarnib) for the treatment of patients with progeria. It is the first and only treatment approved in Europe for this specific indication. In addition, another possible catalyst would be Emergency Use Authorization (EUA) for Peginterferon Lambda for Covid-19 infection. The company is engaging with the FDA and intends to submit an EUA application along with the full set of results from the TOGETHER study. It was done in a predominantly vaccinated patient population, so it remains to be seen how well it does if it is ultimately approved. Regardless, I believe EUA could act as a trade opportunity. These are the reasons why I believe that Eiger BioPharmaceuticals is a great speculative biotech play to look into. Lonafarnib Catalyst Expected End Of 2022 Lonafarnib is in clinical development for the treatment of patients with Hepatitis Delta Virus. Hepatitis Delta Virus ((HDV)) or Hepatitis D is a very small circular RNA virus. It is one of the smallest types of virus that infects humans. However, right off the bat I will tell you that it is rare. Why is it rare? That's because in order for the HDV to infect someone, they also have to be carrying Hepatitis B (HBV). That's right, HDV needs HBV in order to infect a person. That's the only way HDV can replicate in liver cells. Those who may be at risk of getting HDV are those who have gone through many blood transfusions and those who are intravenous types of drug abusers. Symptoms of those who have this virus are as follows: Abdominal type pain Nausea Fatigue Being rare, there are roughly only about less than 200,000 people in the United States who have it. Eiger estimates that an HDV product could be about a >$1 billion per year market opportunity. The good news is that this program is already ongoing and still enrolling patients. This is known as the phase 3 D-LIVR study, which is estimated to enroll about 400 patients total. At least 300 patients will be treated with Lonafarnib. There are going to be two arms in the study as follows: All oral arm of LNF (lonafarnib) boosted with RTV (ritonavir) LNF boosted with RTV combined with pegylated interferon-alfa (PEG IFN-alfa) Each of the 2 arms above are going to be compared to placebo. That means in order for this study to be successful, it just needs to meet the primary endpoint compared to placebo. The composite primary endpoint is twofold as follows: Compare composite virologic and biochemical response rate at end of treatment ((EOT)) in patients who receive 50 mg Lonafarnib/100 mg BID Ritonavir versus patients who receive placebo (over 48 weeks) Compare composite virologic and biochemical response rate at end of EOT in patients who receive 50 mg Lonafarnib/100 mg BID Ritonavir and 180 mcg QW PEG IFN-alfa-2a (over 48 weeks)
Seeking Alpha • Jul 20

European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy

Eiger BioPharmaceuticals (NASDAQ:EIGR) on Wednesday said the European Commission had granted a marketing authorization to its treatment Zokinvy (lonafarnib) for progeria, which is a progressive genetic disorder that causes accelerated aging. The specific indication for which Zokinvy was approved was as a breakthrough therapy in children and young adults with Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies. The European approval for Zokinvy is valid in all 27 EU member states as well as Iceland, Liechtenstein and Norway. EIGR says Zokinvy is the first and only treatment approved in Europe for progeria. The therapy was approved by the U.S. FDA in 2020. EIGR stock +2.8% to $8.73 in early trading.

株主還元

EIGR.QUS BiotechsUS 市場
7D0%1.2%1.0%
1Y-5.6%34.9%28.7%

業界別リターン: EIGR.Q過去 1 年間で34.9 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: EIGR.Qは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。

価格変動

Is EIGR.Q's price volatile compared to industry and market?
EIGR.Q volatility
EIGR.Q Average Weekly Movement12.9%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

安定した株価: EIGR.Qの株価は、 US市場と比較して過去 3 か月間で変動しています。

時間の経過による変動: EIGR.Qの 週次ボラティリティ は過去 1 年間で39%から13%に減少しましたが、依然としてUS株の 75% よりも高くなっています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
n/a25David Apelianwww.eigerbio.com

商業段階のバイオ医薬品会社であるアイガー・バイオファーマシューティカルズ・インクは、肝炎デルタウイルス（HDV）およびその他の重篤な疾患に対する治療法の開発に注力している。同社は、ハッチンソン・ギルフォード・プロジェリア症候群およびプロセッシング不全プロジェロイド・ラミノパチーの治療薬としてゾキンビーを提供している。同社の製品候補には、HDV感染を対象とした臨床第3相試験を完了した経口投与のファルネシル化阻害剤ロナファルニブ、HDVを対象とした臨床開発中のペグインターフェロンラムダ（ラムダ）、軽度および中等度のCOVID-19を対象とした第II相および第III相試験中のラムダ、先天性高インスリン血症および肥満後低血糖症を対象とした第II相試験中のアベキシチドがある。本社はカリフォルニア州パロアルト。2024年4月1日、アイガー・バイオファーマシューティカルズ・インクはその関連会社とともに、テキサス州北部地区連邦破産裁判所に連邦破産法第11条に基づく任意整理を申請した。

Eiger BioPharmaceuticals, Inc. 基礎のまとめ

Eiger BioPharmaceuticals の収益と売上を時価総額と比較するとどうか。
EIGR.Q 基礎統計学
時価総額US$12.59m
収益（TTM）-US$74.96m
売上高(TTM)US$15.77m
0.8x
P/Sレシオ
-0.2x
PER（株価収益率

EIGR.Q は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
EIGR.Q 損益計算書（TTM）
収益US$15.77m
売上原価US$24.00k
売上総利益US$15.75m
その他の費用US$90.71m
収益-US$74.96m

直近の収益報告

Dec 31, 2023

次回決算日

該当なし

一株当たり利益（EPS）-50.62
グロス・マージン99.85%
純利益率-475.26%
有利子負債／自己資本比率-284.4%

EIGR.Q の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2024/10/02 21:35
終値2024/10/01 00:00
収益2023/12/31
年間収益2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Eiger BioPharmaceuticals, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11

アナリスト機関
Madhu KumarBaird
Brian SkorneyBaird
Madhu KumarB. Riley Securities, Inc.